tradingkey.logo

Enliven Therapeutics appoints Rick Fair as new CEO, shares down

ReutersDec 11, 2025 2:43 PM

Shares of drug developer Enliven Therapeutics ELVN.O down 1.7% at $19.82

Enliven appoints Rick Fair as chief executive officer, effective December 11

Sam Kintz, co-founder and former CEO of Enliven, will assume a new role as Head of Pipeline, effective December 11

Enliven plans to initiate a late-stage study of its experimental drug, ELVN-001, in patients with chronic myeloid leukemia in 2026

Including session's moves, stock down 10.4% YTD

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Related Articles

Tradingkey
KeyAI